Shire

ShireShire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Shire RSS Channel

Display # 
Title Published Date
Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA 09 August 2016
One family's history of the rare condition Fabry disease through the generations 28 April 2016
Shire to combine with Baxalta, creating the global leader in rare diseases 14 January 2016
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service 09 December 2015
Shire acquires Meritage Pharma 24 February 2015
Shire acquires Premacure AB 12 March 2013
Shire and Boston Children's Hospital enter into broad research collaboration 20 November 2012
Shire continued strong product sales performance in Q3 28 October 2011
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc. 18 May 2011
Shire delivers a strong first quarter performance 28 April 2011
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® 10 January 2011
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma 10 September 2010
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships 01 September 2010
Shire Proposes to Expand Specialist Gastrointestinal Portfolio 04 August 2010
Shire Purchases Strategic Site in Massachusetts 01 July 2010
VYVANSE® - new ADHD treatment option - now available in Canada 02 February 2010
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity 26 October 2009
Shire Limited has changed its name to Shire plc 01 October 2008
Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million 04 July 2008
Shire plc accelerating new product sales drive revenue growth of 36% 21 February 2008

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Diabetes drug may also offer vascul…

Obesity and Type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease. Obese and diabetic premenopausal women are most at risk...

Read more

AstraZeneca and Lilly receive FDA F…

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016